Transaction

LVP Pharma invests in Rameda's operations in Egypt for EGP 1.14 billion

Announced

4 June 2026

Target

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Value

$21.7m

Asset class

Private Equity

Type

Investment

Instrument

Ordinary Shares (Equity)

Lead investors

LimeVest Partners

Investors

LimeVest Partners

Sector

Healthcare / Pharmaceuticals, Medical Supplies

Markets

Egypt

About the target

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. is an Egypt-based pharmaceutical manufacturer specialising in the production, marketing, sale and storage of pharmaceutical products and diagnostic reagents for human and veterinary use. Established in 1986 and headquartered in Sixth of October City, Egypt, the company manufactures branded generic medicines, nutraceuticals and food supplements across therapeutic areas including alimentary tract and metabolism, systemic anti-infectives, musculo-skeletal system, nervous system and cardiovascular products. Rameda operates through private sales, tenders, exports and toll manufacturing, supplying domestic distributors, government-owned institutions and export agents. The company is listed on the Egyptian Exchange under ticker RMDA.